Please provide your email address to receive an email when new articles are posted on . CHARLOTTE, N.C. — Daily treatment with Xifaxan over 2 weeks improved stool consistency and fecal urgency in ...

A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan ...

Rifaximin SSD failed to significantly delay the onset of HE in patients with liver cirrhosis, but Bausch is yet to scrap the ...

Please provide your email address to receive an email when new articles are posted on . Rifaximin retention decreased with time, with rates of 42% at 180 days dropping to 16% by 540 days. High cost, ...

Rifaximin is a minimally absorbed oral antimicrobial agent that is concentrated in the gastrointestinal tract, has broad-spectrum in vitro activity against gram-positive and gram-negative aerobic and ...

Conclusions Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools.

(This Jan 23 story has been repeated with no changes to the text) Jan 23 (Reuters) - Bausch Health said on Friday its ...

A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a ...

LAVAL, QC / ACCESS Newswire / May 6, 2025 / Bausch Health Companies Inc. (BHC), a global, diversified pharmaceutical company, and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), ...